Bergenbio ASA | MedPath

Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area. • Key late-stage candidates include Debiopharm/Merck's xevinapant, GlaxoSmithKline's dostarlimab, and QBiotics' tigilanol tiglate, each employing novel mechanisms to potentially improve outcomes for patients with limited treatment options. • Multiple clinical trials are underway testing innovative approaches including IAP inhibitors, immune checkpoint blockers, and oncolytic therapies, with several Phase III studies expected to deliver results that could reshape treatment paradigms.

BerGenBio's Bemcentinib Enters Clinical Trial for Advanced Lung Adenocarcinoma

5 months ago

• BerGenBio's bemcentinib is being evaluated in a Phase Ib/II clinical trial in combination with pacritinib for advanced lung adenocarcinoma. • The trial, sponsored by the Mays Cancer Center, aims to address unmet needs in lung cancer treatment by targeting AXL and JAK-STAT3 pathways. • Bemcentinib, a selective AXL kinase inhibitor, is combined with pacritinib, a JAK2 inhibitor, to combat tumor growth and metastasis. • The study, involving 44 patients, is funded by the National Cancer Institute and focuses on safety, tolerability, and efficacy.

BerGenBio's AXL Inhibitor Shows Promise in STK11-Mutated Lung Cancer, Faces Leadership Transition

6 months ago

• BerGenBio highlights a significant unmet need in STK11-mutated lung cancer, a substantial market opportunity for its AXL inhibitor, bemcentinib. • The FDA granted fast-track designation to BerGenBio's treatment, potentially expediting its development and regulatory review process. • Interim data from the BTBC 16 study, evaluating bemcentinib, is expected in early 2025, with final data anticipated as late as 2026. • CEO Martin Olin is stepping down, but will remain until a successor is named, ensuring a smooth leadership transition for the company.

BerGenBio's AXL Inhibitor Receives FDA Fast Track for STK11-Mutated Cancers Amidst Leadership Transition

6 months ago

• BerGenBio's AXL inhibitor receives FDA Fast Track designation, highlighting its potential in treating STK11-mutated cancers, addressing a significant unmet medical need. • The company's Q3 2024 earnings call revealed a stable financial position with $175 million NOK, funding operations until Q3 2025, despite a slight revenue decrease. • Interim data from the BTBC 16 study is expected in early 2025, while final data from the Phase 2 part could be available as late as 2026. • CEO Martin Olin's departure is not expected to impact ongoing activities, with a smooth transition planned until a successor is appointed.